Enovis CORP 10-Q

Item 1. Financial Statements ENOVIS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Dollars in thousands, except per share amounts (Unaudited) Three Months Ended Six Months Ended July 4, 2025 June 28, 2024 July 4, 2025 June 28, 2024 Net sales $ 564,545 $ 525,160 $ 1,123,379 $ 1,041,426 Cost of sales 229,848 236,277 456,453 454,647 Gross profit 334,697 288,883 666,926 586,779 Selling, general and administrative expense 267,074 264,100 536,093 519,791 Research and development expense 30,700 23,479 59,228 46,856 Amortization of acquired intangibles 42,962 40,936 84,774 81,867 Purchase of royalty interest 10,041 — 45,818 — Restructuring charges 716 4,587 4,578 17,498 Operating loss ( 16,796 ) ( 44,219 ) ( 63,565 ) ( 79,233 ) Interest expense, net 9,294 16,969 18,482 36,965 Other expense (income), net ( 436 ) ( 33,836 ) 956 ( 9,601 ) Loss from continuing operations before income taxes ( 25,654 ) ( 27,352 ) ( 83,003 ) ( 106,597 ) Income tax expense (benefit) 10,801 ( 8,908 ) 9,032 ( 16,312 ) Net loss from continuing operations ( 36,455 ) ( 18,444 ) ( 92,035 ) ( 90,285 ) Loss from discontinued operations, net of taxes ( 93 ) ( 68 ) ( 218 ) ( 68 ) Net loss ( 36,548 ) ( 18,512 ) ( 92,253 ) ( 90,353 ) Less: net income attributable to noncontrolling interest from continuing operations - net of taxes 191 126 452 283 Net loss attributable to Enovis Corporation $ ( 36,739 ) $ ( 18,638 ) $ ( 92,705 ) $ ( 90,636 ) Net income (loss) per share - basic and diluted Continuing operations $ ( 0.64 ) $ ( 0.34 ) $ ( 1.62 ) $ ( 1.65 ) Discontinued operations $ — $ — $ — $ — Consolidated operations $ ( 0.64 ) $ ( 0.34 ) $ ( 1.62 ) $ ( 1.65 ) See Notes to Condensed Consolidated Financial Statements. 2 ENOVIS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Dollars in thousands (Unaudited) Three Months Ended Six Months Ended July 4, 2025 June 28, 2024 July 4, 2025 June 28, 2024 Net loss $ ( 36,548 ) $ ( 18,512 ) $ ( 92,253 ) $ ( 90,353 ) Other comprehensive income (loss): Foreign currency translation 112,689 ( 4,208 ) 217,617 ( 69,698 ) Unrealized gain (loss) on hedging activities, net of tax expense (benefit) of $ 12,951 , $( 1,966 ), ( 104 ), and $ 5,735 . ( 125,399 ) ( 6,584 ) ( 166,892 ) 18,207 Amounts reclassified from Accumulated other comprehensive loss: Amortization of pension net actuarial loss, net of tax benefit of $( 4 ), $( 7 ), $( 8 ), and $( 14 ). ( 13 ) ( 33 ) ( 39 ) ( 68 ) Reclassification of hedging gain (loss), net of tax expense (benefit) of $ 187 , $( 158 ), $ 69 , and $( 100 ). 610 ( 544 ) 225 ( 358 ) Other comprehensive income (loss) ( 12,113 ) ( 11,369 ) 50,911 ( 51,917 ) Comprehensive loss ( 48,661 ) ( 29,881 ) ( 41,342 ) ( 142,270 ) Less: comprehensive income attributable to noncontrolling interest 323 109 706 215 Comprehensive loss attributable to Enovis Corporation $ ( 48,984 ) $ ( 29,990 ) $ ( 42,048 ) $ ( 142,485 ) See Notes to Condensed Consolidated Financial Statements. 3 ENOVIS CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS Dollars in thousands, except share amounts (Unaudited) July 4, 2025 December 31, 2024 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 44,074 $ 48,167 Trade receivables, less allowance for credit losses of $ 28,178 and $ 24,466 453,702 407,031 Inventories, net 628,215 547,120 Prepaid expenses 43,775 36,246 Other current assets 110,585 107,882 Total current assets 1,280,351 1,146,446 Property, plant and equipment, net 460,130 404,500 Goodwill 1,781,326 1,692,709 Intangible assets, net 1,341,995 1,317,429 Lease asset - right of use 65,183 68,915 Other assets 92,413 88,778 Total assets $ 5,021,398 $ 4,718,777 LIABILITIES AND EQUITY CURRENT LIABILITIES: Current portion of long-term debt $ 20,029 $ 20,027 Accounts payable 212,016 179,098 Accrued liabilities 336,139 329,873 Total current liabilities 568,184 528,998 Long-term debt, less current portion 1,373,510 1,309,473 Non-current lease liability 48,185 52,461 Other liabilities 450,559 263,516 Total liabilities 2,440,438 2,154,448 Equity: Common stock, $ 0.001 par value; 133,333,333 shares authorized; 57,159,478 and 55,876,517 shares issued and outstanding as of July 4, 2025 and December 31, 2024, respectively 57 56 Additional paid-in capital 3,031,093 2,973,121 Accumulated deficit ( 375,728 ) ( 283,023 ) Accumulated other comprehensive loss ( 77,235 ) ( 127,892 ) Total Enovis Corporation equity 2,578,187 2,562,262 Noncontrolling interest 2,773 2,067 Total equity 2,580,960 2,564,329 Total liabilities and equity $ 5,021,398 $ 4,718,777 See Notes to Condensed Consolidated Financial Statements. 4 ENOVIS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF EQUITY Dollars in thousands, except share amounts (Unaudited) Common Stock Additional Paid-In Capital (Accumulated Deficit) Retained Earnings Accumulated Other Comprehensive Loss Noncontrolling Interest Total Shares Amount Balance at December 31, 2024 55,876,517 $ 56 $ 2,973,121 $ ( 283,023 ) $ ( 127,892 ) $ 2,067 $ 2,564,329 Net income (loss) — — — ( 55,966 ) — 261 ( 55,705 ) Other comprehensive income, net of tax benefit of $ 13,185 — — — — 62,902 122 63,024 Common stock issued for acquisition 971,343 1 44,409 — — — 44,410 Payments of tax withholding for stock-based awards — — ( 3,447 ) — — — ( 3,447 ) Common stock-based award activity 270,781 7,607 — — — 7,607 Balance at April 4, 2025 57,118,641 $ 57 $ 3,021,690 $ ( 338,989 ) $ ( 64,990 ) $ 2,450 $ 2,620,218 Net income (loss) — — — ( 36,739 ) — 191 ( 36,548 ) Other comprehensive income (loss), net of tax expense of $ 13,124 — — — — ( 12,245 ) 132 ( 12,113 ) Common stock-based award activity 40,837 — 9,403 — — — 9,403 Balance at July 4, 2025 57,159,478 57 3,031,093 ( 375,728 ) ( 77,235 ) 2,773 2,580,960 Common Stock Additional Paid-In Capital (Accumulated Deficit) Retained Earnings Accumulated Other Comprehensive Loss Noncontrolling Interest Total Shares Amount Balance at December 31, 2023 54,597,142 $ 55 $ 2,900,747 $ 542,471 $ ( 24,881 ) $ 2,309 $ 3,420,701 Net income (loss) — — — ( 71,998 ) — 157 ( 71,841 ) Other comprehensive loss, net of tax expense of $ 7,752 — — — — ( 40,497 ) ( 51 ) ( 40,548 ) Payments of tax withholding for stock-based awards — — ( 4,772 ) — — — ( 4,772 ) Common stock-based award activity 243,439 — 7,302 — — — 7,302 Balance at March 29, 2024 54,840,581 $ 55 $ 2,903,277 $ 470,473 $ ( 65,378 ) $ 2,415 $ 3,310,842 Net income (loss) — — — ( 18,638 ) — 126 ( 18,512 ) Other comprehensive loss, net of tax benefit of $ 2,131 — — — — ( 11,352 ) ( 17 ) ( 11,369 ) Common stock-based award activity 25,779 — 7,977 — — — 7,977 Balance at June 28, 2024 54,866,360 55 2,911,254 451,835 ( 76,730 ) 2,524 3,288,938 See Notes to Condensed Consolidated Financial Statements. 5 ENOVIS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Dollars in thousands (Unaudited) Six Months Ended July 4, 2025 June 28, 2024 Cash flows from operating activities: Net loss $ ( 92,253 ) $ ( 90,353 ) Adjustments to reconcile net loss to net cash provided by (used in) in operating activities: Depreciation and amortization 142,986 139,167 Impairment of assets — 5,555 Stock-based compensation expense 16,075 14,102 Non-cash interest expense 3,203 2,558 Fair value loss (gain) on contingent acquisition shares 1,787 ( 20,068 ) Loss on currency hedges — 11,123 Deferred income tax expense (benefit) ( 3,673 ) ( 19,412 ) Loss on sale of property, plant and equipment 848 383 Changes in operating assets and liabilities: Trade receivables, net ( 20,824 ) ( 24,807 ) Inventories, net ( 57,282 ) 1,953 Accounts payable 23,161 ( 6,744 ) Other operating assets and liabilities 32,145 ( 41,840 ) Net cash provided by (used in) operating activities 46,173 ( 28,383 ) Cash flows from investing activities: Purchases of property, plant and equipment and intangibles ( 87,631 ) ( 76,333 ) Payments for acquisitions, net of cash received, and investments ( 24,290 ) ( 758,190 ) Cash received upon settlement of derivatives 1,601 ( 4,645 ) Net cash used in investing activities ( 110,320 ) ( 839,168 ) Cash flows from financing activities: Proceeds from borrowings on term credit facility — 400,000 Repayments of borrowings under term credit facility ( 10,000 ) ( 15,000 ) Proceeds from borrowings on revolving credit facilities and other 127,000 940,000 Repayments of borrowings on revolving credit facilities and other ( 54,995 ) ( 446,479 ) Payment of debt issuance costs — ( 703 ) Payments of tax withholding for stock-based awards ( 3,447 ) ( 4,772 ) Proceeds from issuance of common stock, net 1,129 1,177 Deferred consideration payments and other ( 2,265 ) ( 7,174 ) Net cash provided by financing activities 57,422 867,049 Effect of foreign exchange rates on Cash and cash equivalents 2,632 ( 906 ) Decrease in Cash and cash equivalents ( 4,093 ) ( 1,408 ) Cash and cash equivalents, beginning of period 48,167 44,832 Cash and cash equivalents, end of period $ 44,074 $ 43,424 Supplemental disclosures - Non-cash investing activities: Fair value of contingently issuable shares in business acquisition $ — $ 107,877 See Notes to Condensed Consolidated Financial Statements. 6 ENOVIS CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) 1. General Enovis Corporation (the “Company” or “Enovis”) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The Company conducts its business through two operating segments, Prevention & Recovery (“P&R”) and Reconstructive (“Recon”). The P&R segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative disease. The Recon segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The Condensed Consolidated Financial Statements included in this quarterly report have been prepared by the Company in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“GAAP”) for interim financial statements and reflect, in the opinion of management, all adjustments, which consist solely of normal recurring adjustments, necessary to present fairly the Company’s financial position and results of operations as of and for the periods indicated. The Condensed Consolidated Balance Sheet as of December 31, 2024 is derived from the Company’s audited financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been omitted in accordance with the SEC’s rules and regulations for interim financial statements. The Condensed Consolidated Financial Statements included herein should be read in conjunction with the audited financial statements and related footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 (the “2024 Form 10-K”), filed with the SEC on February 26, 2025. The Company makes certain estimates and assumptions in preparing its Condensed Consolidated Financial Statements in accordance with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the Condensed Consolidated Financial Statements, and the reported amounts of revenues and expenses for the periods presented. Actual results may differ from those estimates. 2. Recently Issued Accounting Pronouncements The Company adopted (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures as of December 31, 2024 . The adoption did not have a material impact on the Company’s Consolidated Financial Statements but did require updates to the presentation of certain information for the Company’s segment disclosures. See Note 13 “Segment Information” for additional information regarding the updates made. The Company is currently reviewing updated disclosure requirements related to (“ASU”) 2023-09 — Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is effective for annual periods beginning after December 15, 2024. The ASU does not have a material impact on the Company’s Consolidated Financial Statements but will require updates to the presentation of certain information for the Company’s income tax disclosures for its annual filing. There is no impact to the Company’s quarterly consolidated financial statements. Other recently issued accounting pronouncements are not expected to have a material impact on the Company's quarterly consolidated financial statements. 7 ENOVIS CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued) (Unaudited) 3. Acquisitions and Investments 2025 Acquisitions In the second quarter of 2025, the Company completed a business combination of a distributor and an asset acquisition of intellectual property for total consideration of $ 7.3 million. In the first quarter of 2025, the Company completed an asset acquisition of intellectual property and four business combinations, including the acquisitions of two P&R businesses and two distributors for total consideration of $ 29.7 million, including deferred and estimated contingent consideration. Of the 2025 transactions mentioned, three are in the P&R segment and four are in the Recon segment. For the transactions in P&R completed during the six months ended July 4, 2025, the Company (i) paid a total of $ 6.8 million, net of cash received, and recorded estimated contingent consideration for future expected payments of $ 1.9 million for the acquisition of two businesses, and (ii) paid a total of $ 6.5 million in cash and recorded a $ 8.3 million liability for deferred payments for an asset acquisition of intellectual property. The transactions added complementary product offerings to the P&R segment. For the transactions in Recon completed during the six months ended July 4, 2025, the Company (i) paid a total of $ 9.5 million, net of cash received, and recorded estimated contingent consideration for future expected payments of $ 0.9 million for three business combinations of distributors, and (ii) paid $ 1.5 million in cash for an asset acquisition of intellectual property. The transactions expanded distribution partners for the Company’s surgical implant products in Europe and added a complementary surgical product technology. The business combinations acquisitions are accounted for under the acquisition method of accounting, and accordingly, the Consolidated Financial Statements include the financial position and results of operations from the acquisition dates. The Company preliminarily recorded approximately $ 35.2 million in definite-lived intangible assets associated with the acquisitions. Purchase accounting procedures are ongoing and revisions may be recorded in future periods during the measurement period. The intellectual property acquisitions are accounted for as asset acquisitions. 2024 Acquisitions On January 3, 2024, the Company acquired LimaCorporate S.p.A. (“Lima”), a privately held global orthopedic company, at an enterprise value of € 800 million (the “Lima Acquisition”), consisting of (i) approximately € 700 million in cash consideration, which includes the repayment at closing of certain indebtedness of Lima and (ii) 1,942,686 shares of common stock of Enovis, par value $ 0.001 per share (the “Contingent Acquisition Shares”), based upon a € 100 million value divided by the 30-day volume weighted average price of Enovis common stock as of the close of business on September 21, 2023. The Contingent Acquisition Shares were issuable in two equal tranches within six and twelve months of the acquisition date upon non-occurrence of certain future events, in each case subject to certain adjustments and conditions as provided for in the purchase agreement. The first tranche of Contingent Acquisition Shares was issued to the seller on July 16, 2024 and the second tranche was issued on January 15, 2025. The cash paid for acquisition was $ 757.7 million, net of acquired cash. Since the acquisition occurred at the beginning of 2024, the results of operations are fully included in both periods presented, and the purchase accounting was finalized as of December 31, 2024. See Note 5, “Acquisitions” in the Notes to Consolidated Financial Statements in the Company’s 2024 Form 10-K for further information regarding the Lima Acquisition. The Company also completed one distributor acquisition in its Reconstructive segment in the second quarter of 2024 and one distributor acquisition in its Prevention & Recovery segment in the third quarter of 2024 for aggregate purchase consideration of $ 4.0 million. Investments As of July 4, 2025, the balance of investments held by the Company without readily determinable fair values was $ 20.4 million. The majority of these investments are carried at cost less impairments, if any, plus adjustments for fair value indicators from observable price changes in orderly transactions for the identical or similar investment of the same issuer. There have been no impairments or upward adjustments in the current year or since acquisition of these investments. One investment is accounted for under the equity method of accounting and is recorded at the initial investment amount, adjusted each period for the Company’s share of the income or loss. 8 ENOVIS CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued) (Unaudited) 4. Revenue The Company provides orthopedic solutions, including products and services spanning the full continuum of patient care, from injury prevention to rehabilitation. While the Company’s sales are primarily derived from three sales channels including dealers and distributors, insurance, and direct to consumers and hospitals, substantially all of the Company’s revenue is recognized at a point in time. The Company disaggregates its revenue into the following geographic/product type groups within its segments: Three Months Ended Six Months Ended July 4, 2025 June 28, 2024 July 4, 2025 June 28, 2024 (In thousands) Prevention & Recovery: U.S. Bracing & Support $ 120,850 $ 117,537 $ 235,936 $ 222,111 U.S. Other P&R 70,823 67,950 137,445 134,300 International P&R 98,897 92,267 189,773 180,356 Total Prevention & Recovery 290,570 277,754 563,154 536,767 Reconstructive: U.S. Recon 129,493 122,062 267,370 245,797 International Recon 144,482 125,344 292,855 258,862 Total Reconstructive 273,975 247,406 560,225 504,659 Total $ 564,545 $ 525,160 $ 1,123,379 $ 1,041,426 Given the nature of its businesses, the Company does not generally have unsatisfied performance obligations with an original contract duration of greater than one year. The nature of the Company’s contracts gives rise to certain types of variable consideration, including rebates, implicit price concessions, and other discounts. The Company includes estimated amounts of variable consideration in the transaction price to the extent that it is probable there will not be a significant reversal of revenue. Allowance for Credit Losses The Company’s estimate of current expected credit losses on trade receivables considers historical credit loss information that is adjusted for current conditions and reasonable and supportable forecasts. In calculating and applying its current expected credit losses, the Company disaggregates trade receivables into business segments due to risk characteristics unique to each segment given the individual lines of business and market. The business segments are further disaggregated based on either geography or product type. The Company uses a loss rate methodology in calculating its current expected credit losses, considering historical write-offs over a defined lookback period in deriving a historical loss rate. The expected credit loss model considers current conditions and reasonable and supportable forecasts for current and projected macroeconomic factors. A summary of the activity in the Company’s allowance for credit losses included within Trade receivables in the Condensed Consolidated Balance Sheets is as follows: Six Months Ended July 4, 2025 Balance at Beginning of Period Charged to Expense, net Write-Offs, Deductions, and Other, net Foreign Currency Translation Balance at End of Period (In thousands) Allowance for Credit Losses $ 24,466 $ 3,254 $ ( 891 ) $ 1,349 $ 28,178 9 ENOVIS CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued) (Unaudited) 5. Net Income (Loss) Per Share from Continuing Operations Net income (loss) per share from continuing operations was computed using the treasury stock method as follows: Three Months Ended Six Months Ended July 4, 2025 June 28, 2024 July 4, 2025 June 28, 2024 (In thousands, except share and per share data) Computation of Net income (loss) per share from continuing operations - basic: Net income (loss) from continuing operations attributable to Enovis Corporation (1) $ ( 36,646 ) $ ( 18,570 ) $ ( 92,487 ) $ ( 90,568 ) Weighted-average shares of Common stock outstanding – basic 57,133,472 54,855,810 56,959,884 54,772,231 Net income (loss) per share from continuing operations – basic $ ( 0.64 ) $ ( 0.34 ) $ ( 1.62 ) $ ( 1.65 ) Computation of Net income (loss) per share from continuing operations - diluted: Net income (loss) from continuing operations attributable to Enovis Corporation (1) $ ( 36,646 ) $ ( 18,570 ) $ ( 92,487 ) $ ( 90,568 ) Weighted-average shares of Common stock outstanding – basic 57,133,472 54,855,810 56,959,884 54,772,231 Net effect of potentially dilutive securities - stock options and restricted stock units — — — — Weighted-average shares of Common stock outstanding – diluted 57,133,472 54,855,810 56,959,884 54,772,231 Net income (loss) per share from continuing operations – diluted $ ( 0.64 ) $ ( 0.34 ) $ ( 1.62 ) $ ( 1.65 ) (1) Net income (loss) from continuing operations attributable to Enovis Corporation for the respective periods is calculated using Net income (loss) from continuing operations less the continuing operations component of the income attributable to noncontrolling interest, net of taxes. The following table presents the potentially dilutive shares of Common stock from stock-based compensation awards excluded from the calculation of Weighted-average shares of Common stock outstanding – diluted as inclusion would be anti-dilutive in Net income (loss) per share (“Anti-dilutive shares”): Three Months Ended Six Months Ended July 4, 2025 June 28, 2024 July 4, 2025 June 28, 2024 Anti-dilutive shares 2,120,049 1,378,308 1,993,752 1,106,763 In conjunction with the Lima Acquisition, the Company agreed to a contingent issuance of 1,942,686 Contingent Acquisition Shares in two equal tranches within six and twelve months of the acquisition date upon the non-occurrence of certain future events, in each case subject to certain adjustments and conditions as provided for in the purchase agreement. The first tranche of Contingent Acquisition Shares was issued to the seller on July 16, 2024 and the second tranche was issued on January 15, 2025. The Contingent Acquisition Shares were only included in the weighted-average calculation of basic shares when there were no circumstances the shares would not be issued. 10 ENOVIS CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued) (Unaudited) 6. Income Taxes Three Months Ended Six Months Ended July 4, 2025 June 28, 2024 July 4, 2025 June 28, 2024 (In thousands) Loss from continuing operations before income taxes $ ( 25,654 ) $ ( 27,352 ) $ ( 83,003 ) $ ( 106,597 ) Income tax expense (benefit) $ 10,801 $ ( 8,908 ) $ 9,032 $ ( 16,312 ) Effective tax rate: ( 42.1 ) % 32.6 % ( 10.9 ) % 15.3 % The effective tax rate for the three months ended July 4, 2025 differs from the 2025 federal statutory rate of 21%, primarily due to an increase in valuation allowance on U.S. deferred tax assets, which had a significant impact on the effective tax rate. Additionally, non-deductible expenses and U.S. taxation on international operations also contributed to the rate difference. This was partially offset by tax credits for research and development and non-U.S. income taxed at lower rates. The effective tax rate for the six months ended July 4, 2025 differs from the 2025 federal statutory rate of 21%, primarily due to an increase in valuation allowance on U.S. deferred tax assets, which had a significant impact on the effective tax rate. Additionally, non-deductible expenses and U.S. taxation on international operations also contributed to the rate difference. This was partially offset by tax credits for research and development and non-U.S. income taxed at lower rates. The effective tax rate for the three months ended June 28, 2024 was higher than the 2024 U.S. federal statutory rate of 21%, primarily due to tax credits for research and development, non-U.S. income taxed at lower rates and non-taxable fair value gain on contingent acquisition shares. This was partially offset by an increase in valuation allowance on interest limitation carryforwards, non-deductible expenses and U.S. taxation on international operations. The effective tax rate for the six months ended June 28, 2024 was lower than the 2024 U.S. federal statutory rate of 21%, primarily due to an increase in valuation allowance on interest limitation carryforwards, non-deductible expenses and U.S. taxation on international operations. This was partially offset by tax credits for research and development, non-U.S. income taxed at lower rates and non-taxable fair value gain on contingent acquisition shares. On July 4th, 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted, introducing significant changes to U.S. tax law. The Company evaluated the potential impact of OBBBA and reflected relevant changes within the accompanying financial statements for the three and six months ended July 4, 2025; the most significant being an estimated increase to current year U.S. deferred tax assets for which a valuation allowance is required. The Company will continue to evaluate the changes from OBBBA, monitor developments, and assess its tax position as further guidance becomes available. 11 ENOVIS CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued) (Unaudited) 7. Equity Share Repurchase Program In 2018, the Company’s Board of Directors authorized the repurchase of shares of the Company’s Common stock from time-to-time on the open market or in privately negotiated transactions. No repurchases of the Company’s Common stock have been made under this plan since the third quarter of 2018. As of July 4, 2025, the remaining stock repurchase authorization provided by the Board of Directors was $ 100 million. The timing, amount and method of shares repurchased is determined by management based on its evaluation of market conditions and other factors. There is no term associated with the remaining repurchase authorization. Accumulated Other Comprehensive Income (Loss) The following tables present the changes in the balances of each component of Accumulated other comprehensive income (loss) including reclassifications out of Accumulated other comprehensive loss for the six months ended July 4, 2025 and June 28, 2024. All amounts are presented net of tax and noncontrolling interest, if any. Accumulated Other Comprehensive Loss Components Net Unrecognized Pension Benefit Cost Foreign Currency Translation Adjustment Unrealized Gain (Loss) on Hedging Activities Total (In thousands) Balance at January 1, 2025 $ 8,412 $ ( 113,664 ) $ ( 22,640 ) $ ( 127,892 ) Other comprehensive income (loss) before reclassifications: Net actuarial gain 18 — — 18 Foreign currency translation adjustment 1,159 216,203 — 217,362 Loss on hedge activity — — ( 166,891 ) ( 166,891 ) Other comprehensive income (loss) before reclassifications 1,177 216,203 ( 166,891 ) 50,489 Amounts reclassified from Accumulated other comprehensive income (loss) ( 57 ) — 225 168 Net Other comprehensive income (loss) 1,120 216,203 ( 166,666 ) 50,657 Balance at July 4, 2025 $ 9,532 $ 102,539 $ ( 189,306 ) $ ( 77,235 ) Accumulated Other Comprehensive Loss Components Net Unrecognized Pension Benefit Cost Foreign Currency Translation Adjustment Unrealized Loss on Hedging Activities Total (In thousands) Balance at January 1, 2024 $ 5,008 $ ( 2,016 ) $ ( 27,873 ) $ ( 24,881 ) Other comprehensive income (loss) before reclassifications: Foreign currency translation adjustment ( 330 ) ( 69,300 ) — ( 69,630 ) Gain on hedge activity — — 18,207 18,207 Other comprehensive income (loss) before reclassifications ( 330 ) ( 69,300 ) 18,207 ( 51,423 ) Amounts reclassified from Accumulated other comprehensive income (loss) ( 68 ) — ( 358 ) ( 426 ) Net Other comprehensive income (loss) ( 398 ) ( 69,300 ) 17,849 ( 51,849 ) Balance at June 28, 2024 $ 4,610 $ ( 71,316 ) $ ( 10,024 ) $ ( 76,730 ) 12 ENOVIS CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued) (Unaudited) 8. Inventories, Net Inventories, net consisted of the following: July 4, 2025 December 31, 2024 (In thousands) Raw materials $ 101,346 $ 99,636 Work in process 54,999 49,996 Finished goods 557,357 483,582 713,702 633,214 Less: Allowance for excess, slow-moving and obsolete inventory ( 85,487 ) ( 86,094 ) $ 628,215 $ 547,120 9. Debt Long-term debt consisted of the following: July 4, 2025 December 31, 2024 (In thousands) Term loan $ 367,944 $ 377,345 Senior unsecured convertible notes 450,527 449,051 Revolving credit facilities and other 575,068 503,104 Total debt 1,393,539 1,329,500 Less: current portion ( 20,029 ) ( 20,027 ) Long-term debt $ 1,373,510 $ 1,309,473 Term Loan and Revolving Credit Facility The Company’s credit agreement (the “Enovis Credit Agreement”) consists of a $ 900 million revolving credit facility (the “Revolver”) with an April 4, 2027 maturity date and a term loan in an initial aggregate principal amount of $ 400 million, which was funded on January 3, 2024, the date the Lima Acquisition was consummated. The term loan requires quarterly principal repayments at 1.25 % of the initial aggregate principal amount, which is $ 5 million each quarter, and matures on April 4, 2027 (the “2024 Term Loan”). The Revolver contains a $ 50 million swing line loan sub-facility. All facilities under the Enovis Credit Agreement (including the 2024 Term Loan Facility) are secured by certain personal property of the Company and certain of its subsidiaries, subject to limitations and exclusions. The Enovis Credit Agreement contains customary covenants limiting the ability of the Company and its subsidiaries to, among other things, incur debt or liens, merge or consolidate with others, dispose of assets, make investments, or pay dividends. There are also restrictions on repayments of junior financing and amendments to junior financing documents. In addition, the Enovis Credit Agreement contains financial covenants requiring the Company to maintain (i) a maximum senior secured leverage ratio of not more than 3.50 :1.00 for the fiscal quarter ending June 30, 2024 and thereafter, and (ii) a minimum interest coverage ratio of 3.00 :1:00. The Enovis Credit Agreement contains various events of default (including failure to comply with the covenants under the Enovis Credit Agreement and related agreements), and upon an event of default the lenders may, subject to various customary cure rights, require the immediate payment of all amounts outstanding under the Enovis Credit Agreement. As of July 4, 2025, the Company was in compliance with the covenants under the Enovis Credit Agreement. As of July 4, 2025, the weighted-average interest rate of borrowings under the Enovis Credit Agreement was 5.92 % excluding accretion of deferred financing fees, and there was $ 325 million available on the Revolver. Convertible Notes and Capped Calls The Company has $ 460 million aggregate principal senior unsecured convertible notes that were issued in October 2023 via a private placement pursuant to Rule 144A in conjunction with the financing for the Lima Acquisition (the “2028 Notes”). The 2028 Notes have an interest rate of 3.875 %, payable semiannually in arrears on April 15 and October 15 of each year, 13 ENOVIS CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued) (Unaudited) beginning April 15, 2024 and will mature on October 15, 2028 unless earlier repurchased, redeemed, or converted. The effective interest rate on the 2028 Notes is 4.6 %. For the six months ended July 4, 2025, the interest expense on the 2028 Notes was $ 10.4 million, including $ 9.0 million based upon the coupon rate and $ 1.4 million from accretion of the discount. Holders may convert their 2028 Notes in multiples of $1,000 principal amount prior to the close of business April 15, 2028 under the following circumstances: (i) during any calendar quarter commencing after the calendar quarter ending on December 31, 2023 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130 % of the conversion price on each applicable trading day; (ii) during the five business day period after any five consecutive trading day period (the “measurement period”) in which the “trading price” per $1,000 principal amount of 2028 Notes, as determined following a request by a holder of 2028 Notes in accordance with the procedures described in the 2028 Note indenture, for each trading day of the measurement period was less than 98 % of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day; (iii) if the Company calls any or all of the 2028 Notes for redemption, at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date; or (iv) upon the occurrence of specified corporate events as described in the indenture governing the 2028 Notes. In addition, holders may convert their 2028 Notes, in multiples of $1,000 principal amount, at their option at any time beginning on or after April 15, 2028 until the close of business on the second scheduled trading day immediately preceding the maturity date, regardless of the foregoing circumstances. The conversion rate is 17.1474 shares of common stock per $1,000 principal amount of 2028 Notes (equivalent to an initial conversion price of approximately $ 58.32 per share of common stock), subject to adjustment upon the occurrence of certain specified events as set forth in the indenture governing the 2028 Notes. Upon conversion, the Company will pay cash up to the aggregate principal amount of the 2028 Notes to be converted and pay or deliver, as the case may be, cash, shares of common stock or a combination of cash and shares of common stock, at its election, in respect of the remainder. There have been no redemptions or conversions of the 2028 Notes. The Company also entered into privately negotiated capped call transactions in October 2023 with certain of the initial purchasers of the 2028 Notes in conjunction with the financing for the Lima Acquisition. The capped call transactions are intended generally to mitigate potential dilution to the Company’s common stock upon conversion of any Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted notes, as the case may be, with such reduction and/or offset subject to a cap. If, however, the market price per share of common stock exceeds $ 89.72 , the initial cap price of the capped call transactions, there would be a dilutive effect and/or no offset of any cash payments, in each case, attributable to the amount by which the market price of the common stock exceeds the cap price. Other Indebtedness In addition to the d ebt agreements discussed above, the Company is party to overdraft facilities with a borrowing capacity of $ 30.0 million. Total letters of credit and surety bonds of $ 50.1 million were outstanding as of July 4, 2025 . Deferred Financing Fees As of July 4, 2025, t he Company has $ 1.9 million in deferred financing fees included in Other assets related to the Revolver and $ 11.5 million of original issue discount fees and other issuance costs included as a reduction of Long-term debt related to the 2024 Term Loan and the 2028 Notes. 14 ENOVIS CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued) (Unaudited) 10. Accrued Liabilities Accrued liabilities in the Condensed Consolidated Balance Sheets consisted of the following: July 4, 2025 December 31, 2024 (In thousands) Accrued compensation and related benefits $ 83,928 $ 85,989 Derivative liability – current portion 52,253 3,648 Accrued third-party commissions 35,147 34,602 Lease liability - current portion 23,048 22,340 Accrued taxes 19,821 21,341 Accrued rebates 18,015 19,964 Accrued professional fees 12,253 5,003 Purchase of royalty interest 10,432 — Contingent consideration - current portion 10,429 49,719 Accrued royalties 5,186 6,296 Customer advances and billings in excess of costs incurred 5,440 6,229 Accrued interest 5,364 5,841 Accrued freight 4,678 5,314 Warranty liability 2,745 2,818 Accrued restructuring liability 1,247 2,938 Other 46,153 57,831 $ 336,139 $ 329,873 Accrued Restructuring Liability The Company’s restructuring programs include a series of actions to reduce the structural costs of the Company. A summary of the activity in the Company’s restructuring liability included in Accrued liabilities in the Condensed Consolidated Balance Sheets is as follows: Six Months Ended July 4, 2025 Balance at Beginning of Period Provisions Payments Foreign Currency Translation Balance at End of Period (In thousands) Restructuring charges: Termination benefits (1) $ 2,932 $ 3,527 $ ( 5,223 ) $ 5 $ 1,241 Facility closure costs and other (2) 6 1,051 ( 1,051 ) — 6 Total $ 2,938 $ 4,578 $ ( 6,274 ) $ 5 $ 1,247 Non-cash charges (3) 251 Total Provisions (4) $ 4,829 (1) Includes severance and other termination benefits, including outplacement services. (2) Includes the cost of relocating associates, relocating equipment, lease termination expense and other costs in connection with the closure and optimization of office sites, shared service centers, and manufacturing facilities. (3) Non-cash charges are classified as Cost of sales on the Company’s Condensed Consolidated Statements of Operations for the six months ended July 4, 2025. (4) For the six months ended July 4, 2025, $ 3.5 million and $ 1.3 million of the Company’s total provisions were related to the P&R and Recon segments, respectively. 15 ENOVIS CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued) (Unaudited) 11. Financial Instruments and Fair Value Measurements The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance establishes a fair value hierarchy based on the inputs used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows: Level One : Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets. Level Two : Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. Level Three : Inputs to the valuation methodology are unobservable and significant to the fair value measurement. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The carrying values of financial instruments, including trade receivables, other receivables and accounts payable, approximate their fair values due to their short-term maturities. The carrying value of the Company’s term loan and revolving credit facility debt, which bears a variable interest rate indexed to the Secured Overnight Financing Rate (SOFR), approximates fair value as it reprices when market interest rates change. Based on current interest rates for similar types of borrowings, the estimated fair value of the Company’s total debt, including the Senior unsecured convertible notes, the 2024 Term Loan, and the Revolver, was $ 1.4 billion and $ 1.4 billion as of July 4, 2025 and December 31, 2024, respectively. The estimated fair value, a Level Two valuation in the fair value hierarchy, may not represent actual values of the financial instruments that could be realized as of the balance sheet date or that will be realized in the future. As of July 4, 2025, the Company held $ 19.0 million in Level Three liabilities arising from contingent consideration related to acquisitions that may settle in cash. The fair value of the contingent consideration liabilities is determined using unobservable inputs and the inputs vary based on the nature of the purchase agreements. These inputs can include the estimated amount and timing of projected cash flows, the risk-adjusted discount rate used to present value the projected cash flows, and the probability of the acquired company attaining certain targets stated within the purchase agreements. A change in these unobservable inputs to a different amount might result in a significantly higher or lower fair value measurement at the reporting date due to the nature of uncertainty inherent to the estimates. During the six months ended July 4, 2025, the Company recorded a net increase in contingent consideration primarily due to $ 2.8 million from bolt-on acquisitions closed in the first quarter of 2025, partially offset by payments from a prior acquisition. The gross range of outcomes for contingent consideration arrangements that have a fixed limit on the maximum payout is zero to $ 6.7 million. There is one contingent consideration arrangement remaining that has no limit and is based on a percentage of sales in excess of benchmark through 2027. Additionally, in conjunction with the Lima Acquisition, the Company agreed to a contingent issuance of 1,942,686 Contingent Acquisition Shares in two equal tranches within six and twelve months of the acquisition date upon the non-occurrence of certain future events, in each case subject to certain adjustments and conditions as provided for in the purchase agreement. The Contingent Acquisition Shares liability has been fully settled with the first tranche of Contingent Acquisition Shares issued to the seller on July 16, 2024 and the second tranche issued on January 15, 2025. The liability, which was recorded in Accrued liabilities, was adjusted to fair value each reporting period with the adjustments reflected in Other expense (income), net in the Condensed Consolidated Statement of Operations. The fair value adjustments were a loss of $ 1.8 million for the three and six months ended July 4, 2025 and gains of $ 33.5 million and $ 20.1 million for the three and six months ended June 28, 2024, respectively. The fair value of the Contingent Acquisition Shares liability was Level One in the fair value hierarchy as it is determined using the quoted market prices. There were no transfers in or out of Level One, Two or Three during the six months ended July 4, 2025. 16 ENOVIS CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued) (Unaudited) Total Contingent Consideration Rollforward Beginning Balance Additions Charges / (Gain) Interest Payments Foreign Exchange Ending Balance (In thousands) Contingent Consideration - Level One $ 42,622 $ — $ 1,787 $ — $ ( 44,409 ) $ — $ — Contingent Consideration - Level Three 17,315 2,762 — — ( 1,964 ) 881 18,994 Total Contingent Consideration $ 59,937 $ 2,762 $ 1,787 $ — $ ( 46,373 ) $ 881 $ 18,994 Purchase of royalty interest liability In the first and second quarters of 2025, the Company entered into agreements to buyout the economic interest in future royalty payments in connection with the termination of certain legacy product development agreements related to certain of the Company’s U.S. reconstructive products. The aggregate gross buyout amount under such agreements is $ 56.5 million, which will be paid over nine years. The Company recorded charges to the Condensed Consolidated Statements of Operations of $ 10.0 million and $ 45.8 million for the three and six months ended July 4, 2025, respectively, representing the discounted liability upon entering the agreements of which $ 10.4 million is recorded in Accrued liabilities as of July 4, 2025, and the non-current portion is recorded in Other liabilities on the Condensed Consolidated Balance Sheet. Deferred Compensation Plans The Company maintains deferred compensation plans for the benefit of certain employees and non-executive officers. As of July 4, 2025 and December 31, 2024 the fair value of these plans were $ 18.6 million and $ 17.0 million, respectively. These plans are deemed to be Level Two within the fair value hierarchy. Forward Currency Contracts The Company’s objective in using forward currency contracts is to add stability to the Company’s earnings and to protect the U.S. Dollar value of forecasted transactions. To accomplish this objective, the Company has entered into forward currency contract agreements between the U.S. Dollar and the Mexican Peso as part of its risk management strategy. These forward currency contract agreements are designated and qualify as cash flow hedges. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in Unrealized gain (loss) on hedging activities, net of tax within the Company’s unaudited Condensed Consolidated Statements of Comprehensive Income (Loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, the Company recognizes the gain or loss in earnings within Cost of Sales in its unaudited Condensed Consolidated Statements of Operations. The contracts are recorded at fair value and deemed to be Level Two in the fair value hierarchy. At July 4, 2025, the Company’s forward currency contracts have a Mexican Peso notional amount of approximately 506.0 million and a U.S. Dollar aggregate notional amount of $ 24.7 million. During the three and six months ended July 4, 2025, the Company recognized a realized loss of $ 0.3 million and $ 1.5 million, respectively, on its Condensed Consolidated Statements of Operations related to its forward currency contracts designated as cash flow hedges. At June 28, 2024, the Company’s forward currency contracts have a Mexican Peso notional amount of approximately $ 420.0 million and a U.S. Dollar aggregate notional amount of $ 24.0 million. During the three and six months ended June 28, 2024, the Company recognized a realized gain of $ 0.3 million and $ 0.5 million, respectively on its Condensed Consolidated Statements of Operations related to its forward currency contracts designated as cash flow hedges. Net Investment Hedges The Company has cross-currency swap agreements to hedge its net investment in its Swiss Franc-denominated subsidiaries against adverse movements in exchange rates between the U.S. Dollar and the Swiss Franc. These swap agreements are designated and qualified as net investment hedges. These contracts have a Swiss Franc notional amount of approximately 1.22 billion Swiss Franc and a U.S. Dollar aggregate notional amount of $ 1.35 billion as of July 4, 2025. Cross-currency swaps involve the receipt of functional-currency fixed-rate amounts from a counterparty in exchange for the Company making foreign-currency fixed-rate payments over the life of the agreement. For derivatives designated as net investment hedges, the gain or loss on the derivative is reported in the Condensed Consolidated Balance Sheet as part of Accumulated other comprehensive loss and in the Company’s Condensed Consolidated Statements of Comprehensive Income 17 ENOVIS CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued) (Unaudited) (Loss) as part of the foreign currency translation adjustment. Amounts are reclassified out of Accumulated other comprehensive income (loss) into earnings when the hedged net investment is either sold or substantially liquidated. The Company received interest income on its cross-currency swap derivatives of $ 12.0 million and $ 24.3 million for the three and six months ended July 4, 2025 and $ 5.7 million and $ 8.3 million for the three and six months ended June 28, 2024, respectively, which is included within Interest expense, net in the Condensed Consolidated Statements of Operations. The increased benefit reflects the increase in net investment hedging activity with cross-currency swap agreements entered into during the third quarter of 2024. In January 2025, cross-currency swap agreements designated as net investment hedges with a 272 million Swiss Franc notional amount were de-designated and settled for a $ 1.6 million cash inflow reflected within investing activities in the Consolidated Statements of Cash Flows. The $ 2.5 million gain on settlement is reported in the Condensed Consolidated Balance Sheet as part of Accumulated other comprehensive income (loss) and in the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) as part of the foreign currency translation adjustment. The Company contemporaneously entered into new cross-currency swap agreements for the same Swiss Franc notional amount and designated them as a hedge of its net investment in its Swiss Franc-denominated subsidiaries. In April 2024, cross-currency swap agreements designated as net investment hedges with a 403 million Swiss Franc notional amount were de-designated and settled for a $ 4.6 million cash outflow reflected within investing activities in the Consolidated Statements of Cash Flows. The $ 0.7 million gain on settlement is reported in the Condensed Consolidated Balance Sheet as part of Accumulated other comprehensive income (loss) and in the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) as part of the foreign currency translation adjustment. The Company contemporaneously entered into new cross-currency swap agreements for the same Swiss Franc notional amount and designated them as a hedge of its net investment in its Swiss Franc-denominated subsidiaries. The following table presents the effect of the Company’s designated hedging instruments on Accumulated other comprehensive income (loss) for the three and six months ended July 4, 2025 and June 28, 2024: Three Months Ended Six Months Ended July 4, 2025 June 28, 2024 July 4, 2025 June 28, 2024 (In thousands) (In thousands) Gain (loss) on cross-currency swaps $ ( 115,070 ) $ ( 5,965 ) $ ( 173,005 ) $ 25,426 Gain on forward currency contracts 3,420 ( 3,287 ) 6,303 ( 1,942 ) $ ( 111,650 ) $ ( 9,252 ) $ ( 166,702 ) $ 23,484 18 ENOVIS CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued) (Unaudited) Non-Designated Hedging Instruments The Company also used non-designated forward currency contracts for the purpose of managing its exposure to currency exchange rate risk related to the Euro-denominated purchase price of the Lima Acquisition which closed in January 2024. In the first quarter of 2024, the Company recorded a loss of $ 11.1 million on its Consolidated Statements of Operations related to the exchange rate movements over the first three days of 2024. The loss is recorded in Other expense (income), net on the Condensed Consolidated Statements of Operations. From inception of the forward contracts on October 4, 2023 through the closing of the Lima Acquisition on January 3, 2024, the foreign currency forward contracts settled in an overall realized gain position of $ 13.4 million. The following table presents the fair value of the Company’s derivative financial instruments as well as their classification on the Condensed Consolidated Balance Sheets as of July 4, 2025 and December 31, 2024: (In thousands) Location on Unaudited Consolidated Balance Sheets (1) July 4, 2025 December 31, 2024 Derivative Assets Designated Hedging Instruments Forward currency contracts Other current assets $ — $ — Cross-currency swaps Other current assets 35,398 35,376 Total Derivative Assets $ 35,398 $ 35,376 Derivative Liabilities Designated Hedging Instruments Forward currency contracts Accrued liabilities $ 52,253 $ 2,631 Cross-currency swaps Accrued liabilities — 1,017 Cross-currency swaps Other long-term liabilities 176,683 55,463 Total Derivative Liabilities $ 228,936 $ 59,111 (1) The Company classifies derivative assets and liabilities as current when the settlement date of the contract is one year or less. 12. Commitments and Contingencies The Company is involved in various pending legal, regulatory, and other proceedings arising out of the ordinary course of the Company’s business. None of these proceedings are expected to have a material adverse effect on the financial condition, results of operations or cash flow of the Company. With respect to these proceedings, management of the Company believes that either it will prevail, has adequate insurance coverage or has established appropriate accruals to cover potential liabilities. Legal costs related to proceedings or claims are recorded as incurred. Other costs that management estimates may be paid related to the claims are accrued when the liability is considered probable and the amount can be reasonably estimated. There can be no assurance, however, as to the ultimate outcome of any of these matters, and if all or substantially all of these proceedings were to be determined adverse to the Company, there could be a material adverse effect on the financial condition, results of operations or cash flow of the Company. For further description of the Company’s litigation and contingencies, reference is made to Note 18, “Commitments and Contingencies” in the Notes to Consolidated Financial Statements in the Company’s 2024 Form 10-K. 19 ENOVIS CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued) (Unaudited) 13. Segment Information The Company conducts its continuing operations through the Prevention & Recovery and Reconstructive operating segments, which also represent the Company’s reportable segments. ▪ P&R - a leader in orthopedic solutions and recovery sciences, providing devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative disease. • Recon - an innovation market-leader positioned in the fast-growing surgical implant business, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, and surgical productivity tools. The Company’s management, including the chief operating decision maker, evaluates the operating results of each of its reportable segments based upon Net sales and Adjusted EBITDA, which excludes the effect of Other (income) expense, net, non-operating (gain) loss on investments, debt extinguishment charges, interest expense, net, restructuring charges, Medical Device Regulation (MDR) and other costs, strategic transaction costs, stock-based compensation, depreciation and other amortization, acquisition-related intangible asset amortization, purchase of royalty interest, insurance settlement loss (gain), goodwill impairment charges, and inventory step-up charges from the results of the Company’s operating segments. The Company’s segment results were as follows: Three Months Ended Six Months Ended July 4, 2025 June 28, 2024 July 4, 2025 June 28, 2024 (In thousands) Prevention & Recovery: Net sales $ 290,570 $ 277,754 $ 563,154 $ 536,767 Segment cost of sales 131,336 131,586 260,100 259,263 Segment research and development 9,669 9,243 18,910 18,023 Segment operating expense 107,523 100,353 215,367 199,534 Total segment expenses 248,528 241,182 494,377 476,820 Add: Depreciation 4,689 4,569 8,857 9,117 Adjusted EBITDA (non-GAAP) $ 46,731 $ 41,141 $ 77,634 $ 69,064 Reconstructive: Net sales $ 273,975 $ 247,406 $ 560,225 $ 504,659 Segment cost of sales 91,745 80,776 176,905 166,395 Segment research and development 21,031 14,236 40,318 28,833 Segment operating expense 134,738 126,712 273,666 253,230 Total segment expenses 247,514 221,724 490,889 448,458 Add: Depreciation 23,957 23,391 49,354 48,183 Adjusted EBITDA (non-GAAP) $ 50,418 $ 49,073 $ 118,690 $ 104,384 Total: Net Sales $ 564,545 $ 525,160 $ 1,123,379 $ 1,041,426 Adjusted EBITDA (non-GAAP) $ 97,149 $ 90,214 $ 196,324 $ 173,448 20 ENOVIS CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued) (Unaudited) The following is a reconciliation of Net Loss to Adjusted EBITDA: Three Months Ended Six Months Ended July 4, 2025 June 28, 2024 July 4, 2025 June 28, 2024 (In thousands) Net Loss (GAAP) $ ( 36,548 ) $ ( 18,512 ) $ ( 92,253 ) $ ( 90,353 ) Loss from discontinued operations, net of taxes 93 68 218 68 Income tax expense (benefit) 10,801 ( 8,908 ) 9,032 ( 16,312 ) Restructuring charges (1) 920 4,587 4,829 17,498 MDR and other costs (2) 3,318 4,542 6,558 9,460 Strategic transaction costs (3) 13,450 22,693 25,504 43,530 Stock-based compensation 8,668 7,641 16,075 14,041 Depreciation and other amortization 28,588 30,127 58,212 57,300 Amortization of acquired intangibles 42,962 40,936 84,774 81,867 Purchase of royalty interest 10,041 — 45,818 — Inventory step-up 5,998 23,908 18,119 28,985 Interest expense, net 9,294 16,969 18,482 36,965 Other (income) expense, net (4) ( 436 ) ( 33,836 ) 956 ( 9,601 ) Adjusted EBITDA (non-GAAP) $ 97,149 $ 90,214 $ 196,324 $ 173,448 (1) Restructuring charges include $ 0.2 million and $ 0.3 million expense classified as Cost of sales on the Company’s Condensed Consolidated Statements of Operations for the three and six months ended July 4, 2025, respectively. There were no similar charges for the three and six months ended June 28, 2024. (2) MDR and other costs includes (i) $ 2.8 million and $ 5.4 million for the three and six months ended July 4, 2025 and $ 4.4 million and $ 8.8 million for the three and six months ended June 28, 2024, respectively, in non-recurring costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the new medical device regulations in the European Union for devices which were introduced to the market prior to the regulation and (ii) $ 0.4 million and $ 1.1 million for the three and six months ended July 4, 2025 and $ 0.1 million and $ 0.6 million for the three and six months ended June 28, 2024, respectively, of expenses to resolve certain infrequent, non-recurring regulatory or other legal matters. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations. (3) Strategic transaction costs includes: (i) $ 7.8 million and $ 16.5 million for the three and six months ended July 4, 2025 and $ 19.5 million and $ 37.7 million for the three and six months ended June 28, 2024, respectively, related to non-recurring integration costs associated with the Lima Acquisition, which includes payroll and retention costs for roles to be eliminated or that are dedicated to integration activities, professional and consulting fees specifically incurred to consummate the acquisition and advise and facilitate on post-acquisition integration matters including legal entity consolidation, costs associated with rebranding and marketing acquired business under Enovis name, such as marketing materials, trade show redesign costs and product labeling, and integration related costs associated with sales agent and distributor network rationalization, including contract termination and retention expenses, supply chain and portfolio integration, and quality management system consolidation, (ii) $ 5.4 million and $ 8.2 million for the three and six months ended July 4, 2025 and $ 2.0 million and $ 3.0 million for the three and six months ended June 28, 2024, respectively, of non-recurring (non-Lima) acquisition integration costs and other non-recurring project costs for global ERP rationalization and shared service center start-up, and (iii) $ 0.3 million and $ 0.8 million for the three and six months ended July 4, 2025 and $ 1.2 million and $ 2.8 million for the three and six months ended June 28, 2024, respectively, related to the Separation of our former fabrication technology business. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations. (4) Includes the final fair value loss adjustment for the Contingent Acquisition Shares in 2025, and the fair value gain on Contingent Acquisition Shares in 2024, partially offset by a loss on the non-designated forward currency hedge for managing exchange rate risk related to the Euro-denominated purchase price of the Lima Acquisition. 21 ENOVIS CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued) (Unaudited) The Company’s total assets and capital expenditures by segment were as follows: July 4, 2025 December 31, 2024 (In thousands) Total assets (1) : Prevention & Recovery $ 1,944,632 $ 1,955,138 Reconstructive 3,076,766 2,763,639 Total $ 5,021,398 $ 4,718,777 (1) Includes allocation of certain centrally managed assets, including cash and cash equivalents. Three Months Ended Six Months Ended July 4, 2025 June 28, 2024 July 4, 2025 June 28, 2024 (In thousands) Capital expenditures: Prevention & Recovery $ 5,542 $ 5,170 $ 14,335 $ 9,568 Reconstructive 38,827 34,235 73,296 66,765 Total capital expenditures $ 44,369 $ 39,405 $ 87,631 $ 76,333 22